Postbiotic Gamma-Aminobutyric Acid and Camel Milk Intervention as Innovative Trends Against Hyperglycemia and Hyperlipidemia in Streptozotocin-induced C57BL/6J Diabetic Mice

Abstract Diabetes is a serious disease that threatens human health worldwide. The study hypothesis is to investigate the novel trends that may aid in the prevention of diabetic complications. Camel milk was presented as a functional food, and Lactobacillus brevis (KLDS1.0727 and KLDS1.0373) strains were shown to synthesize postbiotic GABA as a potential food additive, which can therapeutically intervene against hyperglycemia and hyperlipidemia in streptozotocin-induced C57BL/6 mice. During a four-week timeframe, body weight and postprandial blood glucose levels were monitored. Post euthanasia, blood plasma was obtained to investigate hyperlipidemia, insulin concentrations, liver, and renal functions. The liver, pancreas, kidney, and spleen underwent histological examinations. The results demonstrated that KLDS1.0727 and KLDS1.0373 (LACS1, LACS2), and camel milk treatments all had a significant influence on hypoglycemic activity, as evidenced by reduced postprandial blood glucose levels. LACS1, LACS2, and camel milk therapy significantly reduced blood hypolipidemic, ALT, and AST levels. Camel milk is recommended for its therapeutic benefits in the treatment of hyperglycemia and hyperlipidemia in the management of diabetes and comorbidities as well as, GABA which is considered a potential food additive.